1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Relapsing-Remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-Remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-Remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 2 | Active not recruiting | Immunic AG | 210 | 2019-01-28 | 2024-04-24 |
Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
Tablets (1)
Immunic AG (1)
Bulgaria (1) · Poland (1) · Romania (1) · Ukraine (1)
Andreas Muehler (1)
2018 (1)